Comparison of Biweekly and Triweekly Therapy With Docetaxel and Irinotecan for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer

The Showa University Journal of Medical Sciences
doi 10.15369/sujms1989.19.103
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Showa University Society

Related search

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2017English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Phase I Study of Celecoxib With Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer

Frontiers in Oncology
Cancer ResearchOncology
2011English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

A Phase II Trial of Docetaxel and Ifosfamide for Patients With Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting

Cancer Research and Treatment
Cancer ResearchOncology
2004English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy